Strides Pharma Science Ltd Stock Price Today (NSE: STAR)
Fundamental Score
Strides Pharma Science Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Strides Pharma Science Ltd share price today is ₹937.75, up +1.19% on NSE/BSE as of 30 March 2026. Strides Pharma Science Ltd (STAR) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.41K (Cr). The 52-week high for STAR share price is ₹1025.00 and the 52-week low is ₹513.05. At a P/E ratio of 19.35x, STAR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 150.67% and a debt-to-equity ratio of 0.67.
Strides Pharma Science Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Strides Pharma Science Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Strides Pharma Science Share Price: A Financial Analysis
A critical trend in the pharmaceutical industry is the increasing demand for affordable generics, particularly in emerging markets. This analysis focuses on understanding the dynamics influencing the Strides Pharma Science share price, currently trading at ₹863.90. This assessment examines the company's valuation metrics, profitability, and competitive positioning within the pharmaceutical sector. The current Price-to-Earnings (PE) ratio of 19.35 suggests the market has moderate expectations for future earnings growth.
A key metric to consider when evaluating a pharmaceutical company is its Return on Capital Employed (ROCE). Strides Pharma Science’s ROCE of 14.68% indicates its efficiency in generating profits from its capital investments. A strong ROCE contributes to building a robust economic moat, allowing the company to reinvest in research and development, expand its product portfolio, and maintain a competitive edge. This allows Strides to increase their margins.
Comparing Strides Pharma Science with its peers provides valuable context. While a detailed management quality comparison requires deeper qualitative analysis, observations suggest
Mankind Pharma Ltd demonstrates potentially stronger leadership strategies, given its market capitalization and growth trajectory. More information is needed to accurately analyze differences in quality.This analysis of Strides Pharma Science Ltd. is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra. It uses factual data and observational language and is for informational purposes only. It is not a recommendation to buy or sell the shares of Strides Pharma Science Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Strides Pharma Science Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of STAR across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (150.67%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 19.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (79.67%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (122.76% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (124.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹1000.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 41.49%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Low Promoter Commitment (27.86%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (44.13%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Strides Pharma Science Ltd Financial Statements
Comprehensive financial data for Strides Pharma Science Ltd including income statement, balance sheet and cash flow
About STAR (Strides Pharma Science Ltd)
Strides Pharma Science Ltd is a global pharmaceutical entity carving a niche through its broad spectrum of development, manufacturing, and commercialization of diverse pharmaceutic...al products. It operates across a wide geographical footprint, strategically positioning itself in key markets across Africa, Australia, North America, Europe, and Asia. The company excels in producing a comprehensive range of finished dosage forms, catering to various therapeutic needs through an array of product formats. This includes everything from conventional tablets and capsules, both hard and soft gelatin, to more specialized formulations like sachets, liquids, nasal sprays, gels, and topical treatments like ointments and creams. This multifaceted approach allows Strides to effectively meet the demands of diverse patient populations and healthcare providers worldwide. Beyond its generic offerings, Strides Pharma is actively involved in the development and marketing of branded generic products, focusing on therapeutic areas with significant growth potential and unmet medical needs. The company has a particular emphasis on chronic therapies, addressing long-term health conditions that require sustained treatment and management. These strategic therapeutic areas encompass women's health, recognizing the specific healthcare needs of women across different life stages, and the central nervous system, targeting neurological and psychiatric disorders. Furthermore, Strides is committed to developing solutions for cardiovascular ailments, reflecting the increasing prevalence of heart-related diseases globally. This focus on branded generics allows Strides to differentiate itself in the market and provide value-added products for both patients and prescribers. Strides Pharma's strength lies in its ability to integrate research and development, manufacturing excellence, and strategic commercial partnerships to deliver high-quality pharmaceutical products to a global audience. Its vertically integrated structure, encompassing API sourcing, formulation development, and commercialization, enables efficient cost management and robust quality control. The company's commitment to innovation, coupled with its deep understanding of regulatory landscapes across various markets, allows it to navigate the complexities of the pharmaceutical industry effectively. By continuously adapting to evolving market dynamics and investing in future growth opportunities, Strides Pharma Science is positioned to sustain its momentum and expand its reach in the years to come.
Company Details
Key Leadership
Corporate Events
Latest News
STAR Share Price: Frequently Asked Questions
What is the current share price of Strides Pharma Science Ltd (STAR)?
As of 30 Mar 2026, 12:03 pm IST, Strides Pharma Science Ltd share price is ₹937.75. The STAR stock has a market capitalisation of ₹8.41K (Cr) on NSE/BSE.
Is STAR share price Overvalued or Undervalued?
STAR share price is currently trading at a P/E ratio of 19.35x, compared to the industry average of 31.77x. Based on this relative valuation, the Strides Pharma Science Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of STAR share price?
The 52-week high of STAR share price is ₹1025.00 and the 52-week low is ₹513.05. These values are updated daily from NSE/BSE price data.
What factors affect the Strides Pharma Science Ltd share price?
Key factors influencing STAR share price include quarterly earnings growth (Sales Growth: 4.62%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Strides Pharma Science Ltd a good stock for long-term investment?
Strides Pharma Science Ltd shows a 5-year Profit Growth of 124.04% and an ROE of 150.67%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.67 before investing in STAR shares.
How does Strides Pharma Science Ltd compare with its industry peers?
Strides Pharma Science Ltd competes with major peers in the Pharmaceuticals. Investors should compare STAR share price P/E of 19.35x and ROE of 150.67% against the industry averages to determine competitive standing.
What is the P/E ratio of STAR and what does it mean?
STAR share price has a P/E ratio of 19.35x compared to the industry average of 31.77x. Investors pay ₹19 for every ₹1 of annual earnings.
How is STAR performing according to Bull Run's analysis?
STAR has a Bull Run fundamental score of 31.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does STAR belong to?
STAR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Strides Pharma Science Ltd share price.
What is Return on Equity (ROE) and why is it important for STAR?
STAR has an ROE of 150.67%, which indicates excellent management efficiency. ROE measures how efficiently Strides Pharma Science Ltd generates profits from shareholders capital.
How is STAR debt-to-equity ratio and what does it indicate?
STAR has a debt-to-equity ratio of 0.67, which indicates moderate leverage that should be monitored.
What is STAR dividend yield and is it a good dividend stock?
STAR offers a dividend yield of 0.44%, meaning you receive ₹0.44 annual dividend for every ₹100 invested in Strides Pharma Science Ltd shares.
How has STAR share price grown over the past 5 years?
STAR has achieved 5-year growth rates of: Sales Growth 10.65%, Profit Growth 124.04%, and EPS Growth 122.76%.
What is the promoter holding in STAR and why does it matter?
Promoters hold 27.86% of STAR shares, with 44.13% pledged. High promoter holding often indicates strong management confidence in Strides Pharma Science Ltd.
What is STAR market capitalisation category?
STAR has a market capitalisation of ₹8408 crores, placing it in the Mid-cap category.
How volatile is STAR stock?
STAR has a beta of N/A. A beta > 1 suggests the Strides Pharma Science Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is STAR operating profit margin trend?
STAR has a 5-year average Operating Profit Margin (OPM) of 10.16%, indicating the company's operational efficiency.
How is STAR quarterly performance?
Recent quarterly performance shows Strides Pharma Science Ltd YoY Sales Growth of 4.62% and YoY Profit Growth of 79.67%.
What is the institutional holding pattern in STAR?
STAR has FII holding of 28.51% and DII holding of 12.98%. Significant institutional holding often suggests professional confidence in the Strides Pharma Science Ltd stock.